How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.94, Iss.2, 2005-11, pp. : 153-159

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?

By Persiani Roberto

Annals of Surgical Oncology, Vol. 16, Iss. 4, 2009-04 ,pp. : 1077-1079

Springer Publishing Company

Access to resources Recommend Favorite

Should oral bisphosphonates be standard of care in women with early breast cancer?

By Clemons Mark

Breast Cancer Research and Treatment, Vol. 90, Iss. 3, 2005-04 ,pp. : 315-318

Springer Publishing Company

Access to resources Recommend Favorite

Ductal carcinoma in situ: how should we treat it?

By Bayraktar Soley Arun Banu Glück Stefan

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 245-256

Future Medicine

Access to resources Recommend Favorite

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

By Lipton Allan

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 627-636

Springer Publishing Company

Access to resources Recommend Favorite

Does folate intake decrease risk of postmenopausal breast cancer among women with a family history?

By Sellers Thomas A.

Cancer Causes and Control, Vol. 15, Iss. 2, 2004-03 ,pp. : 113-120

Springer Publishing Company

Access to resources Recommend Favorite